KLP Kapitalforvaltning AS Grows Position in Pfizer Inc. $PFE

KLP Kapitalforvaltning AS lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 2.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,089,732 shares of the biopharmaceutical company’s stock after purchasing an additional 82,300 shares during the quarter. KLP Kapitalforvaltning AS owned 0.05% of Pfizer worth $78,726,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Sather Financial Group Inc grew its stake in Pfizer by 9.8% in the 3rd quarter. Sather Financial Group Inc now owns 10,758 shares of the biopharmaceutical company’s stock worth $274,000 after buying an additional 963 shares in the last quarter. WP Advisors LLC grew its position in Pfizer by 0.5% in the third quarter. WP Advisors LLC now owns 531,344 shares of the biopharmaceutical company’s stock worth $13,539,000 after acquiring an additional 2,539 shares in the last quarter. O Brien Wealth Partners LLC bought a new position in Pfizer in the third quarter valued at $49,000. Code Waechter LLC raised its position in Pfizer by 9.3% during the third quarter. Code Waechter LLC now owns 22,511 shares of the biopharmaceutical company’s stock valued at $552,000 after purchasing an additional 1,911 shares in the last quarter. Finally, North Star Investment Management Corp. lifted its stake in Pfizer by 0.7% during the third quarter. North Star Investment Management Corp. now owns 172,849 shares of the biopharmaceutical company’s stock worth $4,404,000 after purchasing an additional 1,134 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Performance

NYSE:PFE opened at $25.44 on Wednesday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.69. The firm has a market cap of $144.63 billion, a PE ratio of 14.79 and a beta of 0.47. The business has a 50 day moving average price of $25.21 and a 200-day moving average price of $24.94.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. The company had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.8%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio is currently 100.00%.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer announced a multi‑year collaboration with Cartography Biosciences to discover tumor‑selective antigens, which could expand its oncology pipeline and add future revenue/catalysts. Cartography Biosciences and Pfizer to Collaborate on the Discovery of Tumor‑Selective Antigens
• Positive Sentiment: Coverage noting Pfizer’s discounted valuation and recent M&A (Seagen) highlights potential upside if the company executes on oncology and obesity programs — supports the argument that the stock is attractively priced for value/dividend investors. These 3 Stocks Trade at Discounts the Market Won’t Ignore Forever
• Neutral Sentiment: Analysts and retail investors are giving PFE attention for its dividend yield and recent price weakness — this interest can stabilize flows but isn’t an earnings catalyst by itself. Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
• Neutral Sentiment: Pfizer is included in dividend and income‑focused writeups comparing it to peers (e.g., Ford), which may maintain demand from yield‑seeking investors but won’t move fundamentals. Better Dividend Stock: Ford vs. Pfizer
• Neutral Sentiment: Reports that Pfizer plans modest price increases across a number of medicines could lift revenue modestly, but political/PR risk around drug pricing remains a balancing factor. Pfizer (PFE) Plans Price Increases on About 80 Medicines Despite Broader Pricing Deals
• Neutral Sentiment: Pfizer invited the public to its JP Morgan Healthcare Conference webcast (CEO Bourla), which could provide guidance clarity or program updates — a potential short‑term catalyst if management gives new detail. Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
• Negative Sentiment: UBS initiated a Hold on PFE citing a patent‑cliff overhang and an uncertain pipeline that offsets obesity program upside — a formal downgrade/hold stance can weigh on sentiment. Patent Cliff Overhang and Uncertain Pipeline Offset Obesity Upside, Justifying Hold on Fairly Valued Pfizer Shares
• Negative Sentiment: Analysis of Pfizer’s 2026 guidance warns continued margin pressure and slower growth into 2026, which supports cautious positioning by investors. Pfizer: 2026 Guidance Points To Continued Margin And Growth Pressure
• Negative Sentiment: Analyst previews ahead of Q4 flag an expected low double‑digit profit decline, which reinforces the near‑term earnings risk profile. Pfizer’s Quarterly Earnings Preview: What You Need to Know

Wall Street Analyst Weigh In

PFE has been the topic of a number of research reports. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Sanford C. Bernstein reiterated a “market perform” rating and set a $30.00 price target on shares of Pfizer in a research report on Friday, October 31st. Citigroup started coverage on shares of Pfizer in a research note on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price target on the stock. Wolfe Research set a $24.00 price objective on shares of Pfizer and gave the company an “underperform” rating in a research note on Wednesday, December 17th. Finally, Cowen reiterated a “hold” rating on shares of Pfizer in a research report on Tuesday, December 30th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Pfizer presently has an average rating of “Hold” and an average target price of $27.88.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.